NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
June 21, 2023 16:05 ET
|
NextCure
BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at the JMP Securities Life Sciences Conference
May 09, 2023 07:00 ET
|
NextCure
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
NextCure
Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) Cash of approximately $145...
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 07:00 ET
|
NextCure
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Business Update and Reports Full Year 2022 Financial Results
March 02, 2023 16:05 ET
|
NextCure
Clinical data updates expected in 2023 for all three programsNC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML)Ended 2022 with approximately $160 million in cash...
NextCure to Present at SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
NextCure
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at Upcoming Investor Conferences
November 22, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
November 15, 2022 16:30 ET
|
NextCure
BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and...
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
November 07, 2022 08:05 ET
|
NextCure
BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
November 03, 2022 16:15 ET
|
NextCure
Discontinuing development of our NC318 programAdvancing clinical pipeline: NC410 combination, NC525, and NC762 Extending runway into mid-2025 (an additional 15 months) BELTSVILLE, Md., Nov. 03, 2022...